Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Systemic lupus erythematosus
•
Mixed Connective Tissue Disease
•
Autonomic Neurology
Would you pursue immunosuppression in a patient with mixed connective tissue disease presenting primarily as dysautonomia assuming other causes have been ruled out?
Related Questions
What are some practical tips for tacrolimus management/monitoring in SLE nephritis?
In patients with possible early SLE or undifferentiated disease can multiomics be used to help predict what disease phenotype they will develop?
How do you envision incorporating CAR-T therapy into your clinical practice?
How would you approach the treatment of an SLE patient with refractory mucocutaneous ulcerations and lichenoid skin eruption despite treatment with MMF, Aza, Benlysta, Saphnelo, Rituximab, and JAK inhibitors?
Do you have concerns about the use of red light therapy in a patient with lupus?
How would you approach potentially tapering maintenance mycophenolate mofetil in a patient with a history of class IV LN that has been in remission for >5 years?
How do you guide patients who seek online information about their disease to ensure it is accurate, supports their understanding, and minimizes unnecessary anxiety?
In a patient with strong serologic evidence of SLE presenting with isolated bilateral lower limb sensorimotor neuropathy, normal neuroimaging, and CSF, would you initiate cyclophosphamide with pulse-dose steroids upfront, or reserve escalation (e.g., plasma exchange or immunosuppressants) for cases refractory to steroids?
How do you evaluate and manage patients with lupus who are having issues with decreased libido?
Should HCQ be continued in an asymptomatic SLE patient who has received renal transplant?
